Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Method	

Cell materials	Yes (indicate where	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		We do not use any cells.
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		We do not use any cells.

Experimental animals	Yes (indicate where	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		We do not use any animals.
Animal observed in or captured from the field: Provide species, sex and age where possible		We do not use any animals.
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		We do not use any animals.

Plants and microbes	Yes (indicate where	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		We do not use any plants.
Microbes: provide species and strain, unique accession number if available, and source		We do not use any microbes.

Human research participants	Yes (indicate where	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Method	
Provide statement confirming informed consent obtained from study participants.	Method	
Report on age and sex for all study participants.	Method	

Design

Study protocol	Yes (indicate where	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	Method	

Laboratory protocol	Yes (indicate where	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	Method	

Experimental study design (statistics details)	Yes (indicate where	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination	Method	
Randomisation		Patients are divided by CRS-R.
Blinding	Method	
Inclusion/exclusion criteria	Method	

Sample definition and in-laboratory replication	Yes (indicate where	n/a
State number of times the experiment was replicated in laboratory	Method	
Define whether data describe technical or biological replicates	Method	

Ethics	Yes (indicate where	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Method	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		We do not use any animals.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Method	

Dual Use Research of Concern (DURC)	Yes (indicate where	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		The study is not subject to DURC.

Analysis

Attrition	Yes (indicate	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Method	

Statistics	Yes (indicate	n/a
Describe statistical tests used and justify choice of tests.	Method	

Data Availability	Yes (indicate	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		No datasets are created.
If data are publicly available, provide accession number in repository or DOI or URL.		The data are not publicly available.
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		The data are not reused.

Code Availability	Yes (indicate	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		No code or software are used.
If code is publicly available, provide accession number in repository, or DOI or URL.		No code or software are used.

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: https://dx.doi.org/10.21037/apm-21-1852